FindTrial
Sign In

trastuzumab [Herceptin]

DRUG14 trials

Sponsors

Hoffmann-La Roche

Conditions

Breast CancerGastric CancerHealthy VolunteerNeoplasms

Phase 1

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
TerminatedNCT00811993
Hoffmann-La RocheNeoplasms
Start: 2009-02-28End: 2012-12-31Updated: 2016-11-02
A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe
CompletedNCT01344863
Hoffmann-La RocheHealthy Volunteer
Start: 2011-04-30End: 2012-01-31Updated: 2016-11-02

Phase 2

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
CompletedNCT00444587
Hoffmann-La RocheBreast Cancer
Start: 2007-03-31End: 2011-08-31Updated: 2016-06-21
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
CompletedNCT00717405
Hoffmann-La RocheBreast Cancer
Start: 2008-10-31End: 2014-10-31Updated: 2016-08-02
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
CompletedNCT00811135
Hoffmann-La RocheBreast Cancer
Start: 2008-12-31End: 2015-12-31Updated: 2016-09-29
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
CompletedNCT00885755
Hoffmann-La RocheBreast Cancer
Start: 2009-08-13End: 2013-02-18Updated: 2018-03-29
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
WithdrawnNCT00964704
Hoffmann-La RocheBreast Cancer
Start: 2011-03-31End: 2013-08-31Updated: 2016-11-02
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
CompletedNCT01130337
Hoffmann-La RocheGastric Cancer
Start: 2010-07-31End: 2014-06-30Updated: 2015-10-01
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
TerminatedNCT01290718
Hoffmann-La RocheBreast Cancer
Start: 2011-12-31End: 2012-12-31Updated: 2014-12-17
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
TerminatedNCT01363986
Hoffmann-La RocheBreast Cancer
Start: 2011-09-30End: 2012-06-30Updated: 2014-08-11

Phase 3

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
CompletedNCT01120184
Hoffmann-La RocheBreast Cancer
Start: 2010-07-31End: 2016-09-16Updated: 2024-03-04
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
CompletedNCT02402712
Hoffmann-La RocheBreast Cancer
Start: 2015-05-06End: 2019-02-22Updated: 2019-09-06

Phase 4

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
TerminatedNCT01260194
Hoffmann-La RocheGastric Cancer
Start: 2011-06-30End: 2015-01-31Updated: 2016-11-02

Unknown Phase

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
CompletedNCT01152606
Hoffmann-La RocheBreast Cancer
Start: 2007-08-30End: 2016-05-31Updated: 2018-01-25

Related Papers

Abstract P2-11-07: Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis
Cancer Research2023-03-01
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
2022-10-074 citations
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors
The Oncologist2021-09-0918 citations
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Breast Cancer Research and Treatment2021-03-2120 citations
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
2021-01-2048 citations
Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC)
Cancer Research2020-02-15
Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study
Cancer Research2020-02-15
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
2019-05-3054 citations
A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
2018-11-3030 citations
Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis
Annals of Oncology2018-10-013 citations
Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.
Journal of Clinical Oncology2017-05-209 citations
Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.
Journal of Clinical Oncology2016-05-201 citations
Abstract OT3-01-13: MetaPHER: A phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer
Cancer Research2016-02-153 citations
Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Journal of Clinical Oncology2015-05-2085 citations
NEOHX study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—18 m DFS analysis.
Journal of Clinical Oncology2015-01-2025 citations
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
2012-02-28111 citations
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
2011-10-01308 citations